TAK-385

Phase 2Small molecule

Takeda

TAK-385 is one of 92 small molecule programs targeting Uterine Fibroid. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Uterine FibroidActive, not recruiting

Prostate CancerActive, not recruiting

EndometriosisActive, not recruiting

Uterine FibroidPhase 2

Active, not recruiting

Prostate CancerPhase 1

Active, not recruiting

EndometriosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Novantrone

Pfizer

Preclinical

5 2

TAK-385

Takeda

Phase 2

2 3

Trexall

Alnylam Pharmaceuticals

Duragesic

1 5

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 6

Prednisone/prednisolone

Roche

Preclinical

3 7

Osmitrol

BB. Braun Medical Inc.

Preclinical

—8

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

—9

Naropin

FFresenius Kabi Oncology Ltd.

Preclinical

—10

Therapeutic Hydrocortisone

EEastern Cooperative Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Endometriosis3 trials

Efficacy and Safety of TAK-385 in the Treatment of Endometriosis

Completed· Takeda logo

Takeda·Phase 2·NCT01458301·487 enrolled

Clinical Study to Evaluate Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in Patients With Endometriosis

Completed·AASKA Pharmaceutical Co., Ltd.·Phase 3·NCT03931915·335 enrolled

A Long-term Extension Study of TAK-385 in the Treatment of Endometriosis

Completed· Takeda logo

Takeda·Phase 2·NCT01452685·397 enrolled

Prostate Cancer2 trials

A Study of TAK-385 in Hormone Treatment-naïve Participants With Prostate Cancer

Completed· Takeda logo

Takeda·Phase 1·NCT02141659·43 enrolled

Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer

Completed· Takeda logo

Takeda·Phase 2·NCT02135445·103 enrolled

Atorvastatin1 trial

A Phase 1 Study to Evaluate the Effects of Fluconazole and Atorvastatin on the Pharmacokinetics of TAK-385 in Healthy Subjects

Completed· Takeda logo

Takeda·Phase 1·NCT02093390·40 enrolled

ART1 trial

Bioavailability and Effect of Food on TAK-385 Tablet Formulations in Healthy Participants

Completed· Takeda logo

Takeda·Phase 1·NCT02396147·54 enrolled

Uterine Fibroid1 trial

Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids

Completed· Takeda logo

Takeda·Phase 2·NCT01452659·216 enrolled

2 more indications

Absorption1 trial

TAK-385 Phase I Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability Study

Completed· Takeda logo

Takeda·Phase 1·NCT02252354·12 enrolled

Unspecified1 trial

A Food Effect Study of TAK-385 Final Formulation

Completed· Takeda logo

Takeda·Phase 1·NCT02792062·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for TAK-385. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TAK-385 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TAK-385. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Takeda

TAK-385

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Endometriosis3 trials

Prostate Cancer2 trials

Atorvastatin1 trial

ART1 trial

Uterine Fibroid1 trial

Absorption1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News